PetMeds® to Acquire PetCareRx in Transformative Deal
January 19, 2023
Trending News 🌥️
PETMED ($NASDAQ:PETS): PetMeds® is a leading online pet pharmacy that provides pet medications and supplies to pet owners. With this acquisition, PetMeds® will be able to expand its product offering and reach more pet owners around the United States. With the addition of PetCareRx’s extensive product selection, PetMeds® will now be able to provide pet owners with even more options when it comes to caring for their beloved pets. PetMeds® will benefit from the addition of PetCareRx’s expansive product selection and customer base, while PetCareRx will benefit from PetMeds®’s financial strength and industry-leading customer service. The acquisition of PetCareRx by PetMeds® is expected to have a positive impact on both companies and their customers. With the addition of PetCareRx’s product selection, PetMeds® will be able to offer a wider variety of products and services to pet owners.
Additionally, PetCareRx customers will benefit from PetMeds®’s reliable customer service and competitive prices. With the addition of PetCareRx’s extensive product selection, PetMeds® will be able to offer even more options to pet owners, while PetCareRx customers will benefit from PetMeds®’s reliable customer service and competitive prices.
Stock Price
On Tuesday, PetMeds® announced their plans to acquire PetCareRx, a pet pharmacy. This acquisition represents a significant milestone in PetMeds®’s strategic efforts to expand their offerings and customer base. The news of the acquisition sent PETMED EXPRESS stock soaring, with the stock opening at $19.1 and closing at $19.8, representing a 3.7% increase from the last closing price of 19.1. The acquisition of PetCareRx is expected to further enhance PetMeds®’s customer experience and product offerings. By joining forces, PetMeds® and PetCareRx will be better-positioned to compete in the pet pharmacy industry and offer a more comprehensive selection of products and services to their customers.
The company is confident that the acquisition will be a transformative event for both companies, as it will create a larger and more competitive pet pharmacy business. The combined entity is expected to generate significant cost savings, improved operational efficiencies, and expanded customer reach. Overall, the acquisition of PetCareRx is a strategic move that promises to benefit PetMeds®, its customers, and investors alike. With the increased customer base, greater product selection, and cost savings, PetMeds® is positioned to become a major player in the pet pharmacy industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Petmed Express. More…
| Total Revenues | Net Income | Net Margin |
| 262.3 | 15.68 | 6.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Petmed Express. More…
| Operations | Investing | Financing |
| 22.53 | -8.12 | -24.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Petmed Express. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 169.26 | 31.11 | 6.55 |
Key Ratios Snapshot
Some of the financial key ratios for Petmed Express are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.5% | -16.2% | 7.1% |
| FCF Margin | ROE | ROA |
| 7.4% | 8.4% | 6.9% |
VI Analysis
PETMED EXPRESS is a medium risk investment when assessed by VI Risk Rating. This rating takes into account both financial and business aspects of the company, providing an overall view of the company’s long-term potential. VI App has detected two risk warnings in the company’s income sheet and balance sheet which should be monitored to better understand the sustainability of the company. In terms of financials, PETMED EXPRESS has a moderate amount of debt relative to its total assets, as well as a satisfactory cash flow and solid revenue growth. However, the company’s profit margins are lower than average, indicating potential risks in the future. Business-wise, PETMED EXPRESS has a solid customer base with ongoing sales, but there may be issues related to scalability and market saturation. Additionally, competition in the industry is fierce and could lead to further risks down the road. Overall, PETMED EXPRESS is a medium risk investment, with potential issues on both the financial and business side that need to be monitored. Those interested in investing in the company should register with VI App to gain more insight into the company’s financials and risks. More…
VI Peers
PetMed Express Inc is one of the largest online pet pharmacies in the United States. The company offers a wide range of pet medications, supplies, and products at competitive prices. PetMed Express also offers a wide variety of services, including prescription refill reminders, online pet health information, and a pet health hotline. The company’s main competitors are Oriola Corp, Trxade Health Inc, Yunnan Jianzhijia Health-Chain Co Ltd.
– Oriola Corp ($LTS:0NER)
Oriola Corporation is a Finnish company that provides branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company has a market capitalization of €330.77 million and a return on equity of 7.73%. Oriola Corporation is a leading provider of branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company offers a wide range of products and services, including branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) products, medical devices, and services.
– Trxade Health Inc ($NASDAQ:MEDS)
Trxade Health Inc is a healthcare company that focuses on providing services and products to the healthcare industry. The company has a market cap of 8.16M as of 2022 and a Return on Equity of -110.47%. Trxade Health Inc’s main products and services include healthcare software and services, medical supplies, and pharmaceuticals. The company operates in the United States and Canada.
– Yunnan Jianzhijia Health-Chain Co Ltd ($SHSE:605266)
Yunnan Jianzhijia Health-Chain Co Ltd is a Chinese company that focuses on the development and application of health-related big data technology. The company’s products and services include a health information platform, a health data application platform, and a health management platform. As of 2022, Yunnan Jianzhijia Health-Chain Co Ltd has a market cap of 5.46B and a Return on Equity of 11.7%.
Summary
PETMED EXPRESS is a leading pet medications and supplies company, and its recent acquisition of PetCareRx is seen as a transformative deal. Investors have reacted positively to the news, with the stock price rising on the day of the announcement. Analysts expect the acquisition to expand PETMED EXPRESS’s product offerings and give them access to an additional customer base, increasing their market share and potential for growth. The company is seen as a strong and stable investment, with potential upside in the long term.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
